To Switch or Not to Switch: Managing the Morphologic Complications of HAART

Español (soon!) - November 20, 2008

CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.

Conference

"To Switch or Not to Switch: Managing the Morphologic Complications of HAART"
Graeme Moyle (biography)
English - 2005-11-19 - 37 minutes

(27 slides)

Summary :
Key Points:

- Lipoatrophy may not be fully reversible, so consider avoiding or preemptively switching responsible agents

- Pharmacologic interventions to treat lipodystrophy have demonstrated limited effectiveness and may introduce new issues

- Switching one or more components of HAART is a viable strategy to reduce or prevent toxicities without sacrificing efficacy

- Switching or withdrawal of thymidine analogues is the only intervention proven to partially restore subcutaneous fat

Login

	Please log in and get access to thousands of resources about HIV disease and its treatment.
	Already a member?
	Username :
	Password :

	Lost your password?

Search our database

Find the information that you are looking for in over +3000 resources.

ezCME: HIV - Insulin Resistance - C-Reactive Protein (CRP) - ADHD - Sleep Disorder - Prostate Health - Hemophilia - Transplantation

CMEonHIV is owned by E-MedHosting.com.

Copyright @ 2002-2008 E-MedHosting.com. All rights reserved. Disclaimer | Sponsor Disclaimer
Powered by Multiwebcast - webcast services

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR
BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.